Sold as Lopressor. Every FDA application for this active ingredient. Boxed warning
As of Nov 22, 2026, FDA lists 1 application for Metoprolol fumarate (sold as Lopressor), first approved Dec 27, 1989, with 0 new uses approved and 0 published complete response letters.
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Dec 27, 1989 | LopressorNDA 19786 · New active ingredient, new dosage form | Novartis Pharmaceuticals | 0 | Discontinued |
Of the 32 whose ending is known, 47% met their primary endpoint, 3% missed it and 50% stopped early.
| An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 SubstratesUlcerative Colitis, Crohn's Disease · Sanofi | Phase 1 | Not yet recruiting | Nov 6, 2026 |
| BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic CardiomyopathyCardiomyopathy, Hypertrophic Obstructive · Braveheart Bio, Inc. | Phase 3 | Recruiting | Aug 10, 2026 |
| Predicting Response and Exposure Changes in Cirrhosis for EffectivenessLiver Cirrhosis · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Not applicable | Not yet recruiting | Aug 6, 2026 |
| Comparing Two Heart Medicines for Fast, Irregular Heartbeat (Atrial Fibrillation)Atrial Fibrillation (AF), Atrial Fibrillation With Rapid Ventricular Response · Muhammad Ali Javed | Phase 4 | Not yet recruiting | Jul 15, 2026 |
| MAGNEsium With meToprolol for Rate Control In Atrial FibrillationAtrial Flutter With Rapid Ventricular Response · Wake Forest University Health Sciences | Phase 3 | Recruiting | Jun 8, 2026 |
| Beta-Blockers on Neoadjuvant Immunochemotherapy for Hypertensive Patients With Gastric CancerGastric Cancer (GC) · Nanfang Hospital, Southern Medical University | — | Active, not recruiting | Jun 3, 2026 |
| Dose-Response Interaction of Metoprolol and Sufentanil for Attenuating Hemodynamic Responses in Tracheal IntubationGeneral Anesthesia; Tracheal Intubation · Fujian Provincial Hospital | Phase 4 | Not yet recruiting | May 19, 2026 |
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite AthletesSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes · Enhanced Emirates Limited | Not applicable | Enrolling by invitation | May 6, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA